Skip to main content

Market Overview

Morgan Stanley Maintains on Varian Medical Systems


In a report published Thursday, Morgan Stanley analyst Steve Beuchaw maintained Underweight on Varian Medical Systems (NYSE: VAR), with a $71.00 price target.

According to the report, orders missed consensus by 3 percent in Oncology and 12 percent overall, though US Oncology rebounded after a weak FY13 to largely offset international weakness.

“While it is difficult to precisely call out the trend in US Oncology due to changes to reporting structure, tone on the market was positive and gross orders +13% accelerated from +5% in the September quarter,” the report noted. “Results were at odds with our more negative survey and diligence, and we remain cautious on the market. On the downside, int'l orders were -5% despite a -2% comp, driving a +2.7% total Oncology net order figure against a -1% comp (Exhibit 1). In sum, Oncology order growth remains muted and the Oncology backlog declined 2% qr/qr, leaving us comfortable with our forecast for deceleration in the business into ‘15.”

Some highlights from the report included:

-Guidance for 2Q leaves a high bar for 2H14 -Minor model updates; maintain $71 PT

VAR closed Wednesday at $82.99.

Latest Ratings for VAR

Dec 2020JefferiesDowngradesBuyHold
Oct 2020BairdDowngradesOutperformNeutral
Aug 2020BTIGDowngradesBuyNeutral

View More Analyst Ratings for VAR
View the Latest Analyst Ratings


Related Articles (VAR)

View Comments and Join the Discussion!

Posted-In: Morgan Stanley Steve BeuchawAnalyst Color Analyst Ratings

Latest Ratings

VZIOWells FargoInitiates Coverage On31.0
OMWells FargoInitiates Coverage On63.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at